The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity
Open accessAbstract
BACKGROUND: Recent reports suggest that Clostridium difficile colitis may be evolving into a more severe disease. During the second half of 2002 we noted an increase in the number of patients with severe C. difficile-associated diarrhea (CDAD) in our institution. We describe cases of CDAD at our institution over a 13-year period and investigate changes in illness severity. METHODS: We undertook a retrospective chart review of all cases of CDAD diagnosed at the Centre hospitalier universitaire de Sherbrooke from Jan. 1, 1991, to Dec. 31, 2003. Because the hospital serves a well-defined population of Quebec, we were also able to calculate population-based incidence during this period. We abstracted data on individual patients from patient charts and from hospital and pharmacy computer databases. We defined cases of CDAD as having a positive C. difficile cytotoxicity assay result, or endoscopic or histopathological evidence of pseudomembranous colitis. A case was considered complicated if one or more of the following was observed: megacolon, perforation, colectomy, shock requiring vasopressor therapy, or death within 30 days after diagnosis. RESULTS: A total of 1721 cases of CDAD were diagnosed during the study period. The incidence increased from 35.6 per 100,000 population in 1991 to 156.3 per 100,000 in 2003; among patients aged 65 years or more, it increased from 102.0 to 866.5 per 100,000. The proportion of cases that were complicated increased from 7.1% (12/169) in 1991-1992 to 18.2% (71/390) in 2003 (p < 0.001), and the proportion of patients who died within 30 days after diagnosis increased from 4.7% (8/169) in 1991-1992 to 13.8% (54/390) in 2003 (p < 0.001). A high leukocyte count (20.0 small ha, Cyrillic 10(9)/L or greater) and an elevated creatinine level (200 micromol/L or greater) were strongly associated with adverse outcomes: in 2003, 45 (40.9%) of 110 patients with a high leukocyte count or creatinine level, or both, had complicated CDAD and 28 (25.5%) died within 30 days after diagnosis. After adjustment for age and other confounding factors, patients initially given oral vancomycin therapy had a risk of progression to complicated CDAD that was 79% lower than the risk among patients initially treated with metronidazole (adjusted odds ratio 0.2, 95% confidence interval 0.06-0.8, p = 0.02). INTERPRETATION: An epidemic of CDAD with an increased case-fatality rate has had important consequences on the elderly population of our region. Our observational data suggest that the equivalence of vancomycin and metronidazole in the treatment of CDAD needs to be questioned.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
Kelly, C. P., Pothoulakis, C., & LaMont, J. T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300406 · Cited by 1,321
Antibiotic-Associated Diarrhea
Bartlett, J. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011603 · Cited by 1,197
Asymptomatic Carriage of Clostridium difficile and Serum Levels of IgG Antibody against Toxin A
Kyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420604 · Cited by 935
Teasley, D., Olson, M., Gebhard, R., Gerding, D., Peterson, L., Schwartz, M., & Lee, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91036-x · Cited by 785
Risk factors for Clostridium difficile infection
Bignardi, G. E. (1998) · Journal of Hospital Infection · doi:10.1016/s0195-6701(98)90019-6 · Cited by 647
Clostridium Difficile-Associated Diarrhea and Colitis
Gerding, D. N., Johnson, S., Peterson, L. R., Mulligan, M. E., & Silva, J. (1995) · Infection Control & Hospital Epidemiology · doi:10.1086/648363 · Cited by 631
Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and Complications
Dallal, R. M., Harbrecht, B. G., Boujoukas, A. J., Sirio, C. A., Farkas, L. M., Lee, K. K., & Simmons, R. L. (2002) · Annals of Surgery · doi:10.1097/00000658-200203000-00008 · Cited by 628
Wenisch, C., Parschalk, B., Hasenhundl, M., Hirschl, A. M., & Graninger, W. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.5.813 · Cited by 505
Cited by
Siegel, J. D., Rhinehart, E., Jackson, M., & Chiarello, L. (2007) · American Journal of Infection Control · doi:10.1016/j.ajic.2007.10.007 · Cited by 3,456
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationMcDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E., & McDonald, L. C. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67420-x · Cited by 1,430
Self-citationClostridium difficile infection: new developments in epidemiology and pathogenesis
Rupnik, M., Wilcox, M. H., & Gerding, D. N. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2164 · Cited by 1,380
Clostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Postinfectious Irritable Bowel Syndrome
Spiller, R., & Garsed, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.074 · Cited by 1,024
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Self-citationMcFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872
“There is a growing interest in probiotics for the treatment of AAD and CDD due to the wide availability of probiotics as dietary supplements and the concern over recent outbreaks of severe CDD in Canada and the United Kingdom ( 6 , 15).”
BackgroundEmergence of Clostridium difficile-associated disease in North America and Europe
Kuijper, E. J., Coignard, B., & Tüll, P. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01580.x · Cited by 855
The Changing Epidemiology of Clostridium difficile Infections
Freeman, J., Bauer, M. P., Baines, S. D., Corver, J., Fawley, W. N., Goorhuis, B., Kuijper, E. J., & Wilcox, M. H. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00082-09 · Cited by 826
Tang, J. W., Li, Y., Eames, I., Chan, P. K. S., & Ridgway, G. L. (2006) · Journal of Hospital Infection · doi:10.1016/j.jhin.2006.05.022 · Cited by 667
van Prehn, J., Reigadas, E., Vogelzang, E. H., Bouza, E., Hristea, A., Guery, B., Krutova, M., Norén, T., Allerberger, F., Coia, J. E., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.038 · Cited by 640
The epidemiology of community-acquired Clostridium difficile infection: a population-based study
Khanna, S., Pardi, D. S., Aronson, S. L., Kammer, P. P., Orenstein, R., St Sauver, J. L., Harmsen, S. W., & Zinsmeister, A. R. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.398 · Cited by 622
Pepin, J. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050978 · Cited by 606
Self-citationAntimicrobial‐Associated Risk Factors for Clostridium difficile Infection
Owens, Jr., Donskey, C. J., Gaynes, R. P., Loo, V. G., & Muto, C. A. (2008) · Clinical Infectious Diseases · doi:10.1086/521859 · Cited by 603
O’Grady, N. P., Barie, P. S., Bartlett, J. G., Bleck, T., Carroll, K., Kalil, A. C., Linden, P., Maki, D. G., Nierman, D., Pasculle, W., et al. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318169eda9 · Cited by 600
Narrative Review: The New Epidemic of Clostridium difficile–Associated Enteric Disease
Bartlett, J. G. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00008 · Cited by 599
Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era
Polage, C. R., Gyorke, C. E., Kennedy, M. A., Leslie, J. L., Chin, D. L., Wang, S., Nguyen, H. H., Huang, B., Tang, Y.-W., Lee, L. W., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.4114 · Cited by 593
Impact of Clostridium difficile on Inflammatory Bowel Disease
Issa, M., Vijayapal, A., Graham, M. B., Beaulieu, D. B., Otterson, M. F., Lundeen, S., Skaros, S., Weber, L. R., Komorowski, R. A., Knox, J. F., et al. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.12.028 · Cited by 570
Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada
Pepin, J., Alary, M.-E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D., & Bourassa, C. (2005) · Clinical Infectious Diseases · doi:10.1086/430315 · Cited by 570
Self-citationRelatively Poor Outcome after Treatment of Clostridium difficile Colitis with Metronidazole
Musher, D. M., Aslam, S., Logan, N., Nallacheru, S., Bhaila, I., Borchert, F., & Hamill, R. J. (2005) · Clinical Infectious Diseases · doi:10.1086/430311 · Cited by 504
Multilocus Sequence Typing of Clostridium difficile
Griffiths, D., Fawley, W., Kachrimanidou, M., Bowden, R., Crook, D. W., Fung, R., Golubchik, T., Harding, R. M., Jeffery, K. J. M., Jolley, K. A., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01796-09 · Cited by 475
Role of the Intestinal Microbiota in Resistance to Colonization by Clostridium difficile
Britton, R. A., & Young, V. B. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.059 · Cited by 446
Diagnosis and Treatment of Clostridium difficile in Adults: A Systematic Review
Bagdasarian, N., Rao, K., & Malani, P. N. (2015) · JAMA · doi:10.1001/jama.2014.17103 · Cited by 451
Planche, T. D., Davies, K. A., Coen, P. G., Finney, J. M., Monahan, I. M., Morris, K. A., O'Connor, L., Oakley, S. J., Pope, C. F., Wren, M. W., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70200-7 · Cited by 435
Increase in Clostridium difficile–related Mortality Rates, United States, 1999–2004
Redelings, M. D., Sorvillo, F., & Mascola, L. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1309.061116 · Cited by 429
Cammarota, G., Ianiro, G., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000046 · Cited by 428
Ananthakrishnan, A. N., McGinley, E. L., & Binion, D. G. (2008) · Gut · doi:10.1136/gut.2007.128231 · Cited by 426
Carey-Ann, B. D., & Carroll, K. C. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00016-13 · Cited by 423
Antimicrobial Safety: Focus on Fluoroquinolones
Owens, R. C., & Ambrose, P. G. (2005) · Clinical Infectious Diseases · doi:10.1086/428055 · Cited by 415
Can we identify patients at high risk of recurrent Clostridium difficile infection?
Kelly, C. P. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12046 · Cited by 396
Treatment of Clostridium difficile-associated disease: old therapies and new strategies
Aslam, S., Hamill, R. J., & Musher, D. M. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70215-2 · Cited by 366
Zilberberg, M. D., Shorr, A. F., & Kollef, M. H. (2008) · Emerging Infectious Diseases · doi:10.3201/eid1406.071447 · Cited by 362
Lamontagne, F., Labb??, A.-C., Haeck, O., Lesur, O., Lalancette, M., Patino, C., Leblanc, M., Laverdi??re, M., & P??pin, J. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000236628.79550.e5 · Cited by 359
Clostridium difficile Infection Caused by the Epidemic BI/NAP1/027 Strain
O'Connor, J. R., Johnson, S., & Gerding, D. N. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.073 · Cited by 357
Clostridium difficile infection: epidemiology, risk factors and management
Ananthakrishnan, A. N. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.190 · Cited by 352
Miller, B. A., Chen, L. F., Sexton, D. J., & Anderson, D. J. (2011) · Infection Control & Hospital Epidemiology · doi:10.1086/659156 · Cited by 350
Killgore, G., Thompson, A., Johnson, S., Brazier, J., Kuijper, E., Pepin, J., Frost, E. H., Savelkoul, P., Nicholson, B., van den Berg, R. J., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01484-07 · Cited by 337
Self-citationAntibiotic-Associated Diarrhea: Epidemiology, Trends and Treatment
McFarland, L. V. (2008) · Future Microbiology · doi:10.2217/17460913.3.5.563 · Cited by 333
Valiquette, L., Cossette, B., Garant, M.-P., Diab, H., & Pépin, J. (2007) · Clinical Infectious Diseases · doi:10.1086/519258 · Cited by 330
Abou Chakra, C. N., Pepin, J., Sirard, S., & Valiquette, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098400 · Cited by 328
“We could not use the year 2002 as a cut-off date for the introduction of NAP1/BI/027 strain [8,42], because the timing of its introduction varied considerably between countries and regions, and several studies collected data over long periods overlapping this date (Table 1).”
BackgroundMethodSelf-citationKim, J., Smathers, S. A., Prasad, P., Leckerman, K. H., Coffin, S., & Zaoutis, T. (2008) · Pediatrics · doi:10.1542/peds.2008-0469 · Cited by 321
Nosocomial infections in patients with cancer
Kamboj, M., & Sepkowitz, K. A. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70069-5 · Cited by 318
Gastrointestinal Tract Disorders in Older Age
Dumic, I., Nordin, T., Jecmenica, M., Stojkovic Lalosevic, M., Milosavljevic, T., & Milovanovic, T. (2019) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2019/6757524 · Cited by 314
Barbut, F., Mastrantonio, P., Delmée, M., Brazier, J., Kuijper, E., & Poxton, I. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01824.x · Cited by 297
Treatment of Clostridium difficile Infection
Gerding, D. N., Muto, C. A., & Owens, Jr. (2008) · Clinical Infectious Diseases · doi:10.1086/521860 · Cited by 287
Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008
Kuijper, E. J., Barbut, F., Brazier, J. S., Kleinkauf, N., Eckmanns, T., Lambert, M. L., Drudy, D., Fitzpatrick, F., Wiuff, C., Brown, D. J., et al. (2008) · Eurosurveillance · doi:10.2807/ese.13.31.18942-en · Cited by 287
Miller, M., Gravel, D., Mulvey, M., Taylor, G., Boyd, D., Simor, A., Gardam, M., McGeer, A., Hutchinson, J., Moore, D., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649213 · Cited by 278
Reeves, A. E., Theriot, C. M., Bergin, I. L., Huffnagle, G. B., Schloss, P. D., & Young, V. B. (2011) · Gut Microbes · doi:10.4161/gmic.2.3.16333 · Cited by 270
Fulminant Clostridium difficile Colitis: Patterns of Care and Predictors of Mortality
Sailhamer, E. A. (2009) · Archives of Surgery · doi:10.1001/archsurg.2009.51 · Cited by 261
Clostridium difficile and inflammatory bowel disease
Issa, M., Ananthakrishnan, A. N., & Binion, D. G. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20500 · Cited by 257
Clostridium difficile and the microbiota
Seekatz, A. M., & Young, V. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72336 · Cited by 255
Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection
Spigaglia, P. (2016) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936115622891 · Cited by 254
Ricciardi, R. (2007) · Archives of Surgery · doi:10.1001/archsurg.142.7.624 · Cited by 253
Biology of Clostridium difficile: Implications for Epidemiology and Diagnosis
Karen C., C., & John G., B. (2011) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090110-102824 · Cited by 233
Lewis, B. B., Buffie, C. G., Carter, R. A., Leiner, I., Toussaint, N. C., Miller, L. C., Gobourne, A., Ling, L., & Pamer, E. G. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv256 · Cited by 197
Do NSAIDs, Antibiotics, Infections, or Stress Trigger Flares in IBD?
Singh, S., Graff, L. A., & Bernstein, C. N. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.15 · Cited by 181
Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study
Ouwehand, A. C., DongLian, C., Weijian, X., Stewart, M., Ni, J., Stewart, T., & Miller, L. E. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.053 · Cited by 98
A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics
Allen-Vercoe, E., Reid, G., Viner, N., Gloor, G. B., Hota, S., Kim, P., Lee, C., O’Doherty, K. C., Vanner, S. J., Weese, J. S., et al. (2012) · Canadian Journal of Gastroenterology · doi:10.1155/2012/213828 · Cited by 81
Song, H. J., Kim, J.-Y., Jung, S.-A., Kim, S.-E., Park, H.-S., Jeong, Y., Hong, S. P., Cheon, J. H., Kim, W. H., Kim, H.-J., et al. (2010) · Journal of Korean Medical Science · doi:10.3346/jkms.2010.25.12.1784 · Cited by 58
Clinical Guideline for the Diagnosis and Treatment of Gastrointestinal Infections
The Korean Society of Infectious Diseases, Korean Society for Chemotherapy, & The Korean Society of Clinical Microbiology (2010) · Infection and Chemotherapy · doi:10.3947/ic.2010.42.6.323 · Cited by 18
Metadata
- Authors
- Pepin, J.
- Venue
- Canadian Medical Association Journal
- Publisher
- CMA Joule Inc.
- Published
- 2004-08-31
- Volume
- 171
- Issue
- 5
- Pages
- 466-472
- ISSN
- 0820-3946 (ISSN-L)
- 1488-2329
- OpenAlex
- W2056233231
- Cited by
- 1,128
- References
- 33
- FWCI
- 38.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.